Abstract     Description     Claims     Drawing  

US61984132A   [0001] 
US5677171A   [0007]  [0022] 
US5821337A   [0007]  [0022]  [0060] 
US6054297A   [0007]  [0022] 
US6165464A   [0007]  [0022] 
US6339142B   [0007]  [0022] 
US6407213B   [0007]  [0022] 
US6639055B   [0007]  [0022] 
US6719971B   [0007]  [0022] 
US6800738B   [0007]  [0022] 
US7074404B   [0007]  [0022] 
US20060034842A   [0018]  [0022] 
US20080102069A   [0018]  [0022] 
US5720937A   [0022] 
US5720954A   [0022] 
US5725856A   [0022] 
US5770195A   [0022] 
US5772997A   [0022] 
US6387371B   [0022] 
US6399063B   [0022] 
US6015567A   [0022] 
US6333169B   [0022] 
US4968603A   [0022] 
US8075890B   [0022] 
US5648237A   [0022] 
US7018809B   [0022] 
US6267958B   [0022] 
US6685940B   [0022] 
US6821515B   [0022] 
US7060268B   [0022] 
US7682609B   [0022] 
US7371376B   [0022] 
US6127526A   [0022] 
US6333398B   [0022] 
US6797814B   [0022] 
US6417335B   [0022] 
US6489447B   [0022] 
US7531645B   [0022] 
US7846441B   [0022] 
US7892549B   [0022] 
US8075892B   [0022] 
US6573043B   [0022] 
US6905830B   [0022] 
US7129051B   [0022] 
US7344840B   [0022] 
US7468252B   [0022] 
US7674589B   [0022] 
US7919254B   [0022] 
US6949245B   [0022] 
US7485302B   [0022] 
US7498030B   [0022] 
US7501122B   [0022] 
US7537931B   [0022] 
US7618631B   [0022] 
US7862817B   [0022] 
US7041292B   [0022] 
US6627196B   [0022] 
US7371379B   [0022] 
US6632979B   [0022] 
US7097840B   [0022]  [0058]  [0059] 
US7575748B   [0022] 
US6984494B   [0022] 
US7279287B   [0022] 
US7811773B   [0022] 
US7993834B   [0022] 
US8076066B   [0022] 
US8044017B   [0022] 
US7435797B   [0022] 
US7850966B   [0022] 
US7485704B   [0022] 
US7807799B   [0022] 
US8142784B   [0022] 
US7560111B   [0022]  [0065] 
US7879325B   [0022]  [0065] 
US8241630B   [0022] 
US7449184B   [0022] 
US8163287B   [0022] 
US7700299B   [0022] 
US7981418B   [0022] 
US8247397B   [0022] 
US20100016556A   [0022] 
US20050244929A   [0022] 
US20010014326A   [0022] 
US20030202972A   [0022] 
US20060099201A   [0022] 
US20100158899A   [0022] 
US20110236383A   [0022] 
US20110033460A   [0022] 
US20080286280A   [0022] 
US20050063972A   [0022] 
US20060182739A   [0022] 
US20090220492A   [0022] 
US20030147884A   [0022] 
US20040037823A   [0022] 
US20050002928A   [0022] 
US20070292419A   [0022] 
US20080187533A   [0022] 
US20110250194A   [0022] 
US20120034213A   [0022] 
US20030152987A   [0022] 
US20050100944A   [0022] 
US20060183150A   [0022] 
US20080050748A   [0022] 
US20090155803A   [0022] 
US20100120053A   [0022] 
US20050244417A   [0022] 
US20070026001A   [0022] 
US20080160026A   [0022] 
US20080241146A   [0022] 
US20050208043A   [0022] 
US20050238640A   [0022] 
US20060073143A   [0022] 
US20060193854A   [0022] 
US20060198843A   [0022] 
US20110129464A   [0022] 
US20070184055A   [0022] 
US20070269429A   [0022] 
US20080050373A   [0022] 
US20060083739A   [0022] 
US20090087432A   [0022] 
US20060210561A   [0022] 
US20020035736A   [0022] 
US20020001587A   [0022] 
US20080226659A   [0022] 
US20020090662A   [0022] 
US20060046270A   [0022] 
US20080108096A   [0022] 
US20070166753A   [0022] 
US20080112958A   [0022] 
US20090239236A   [0022] 
US20120034609A   [0022] 
US20120093838A   [0022] 
US20040082047A   [0022] 
US20120065381A   [0022] 
US20090187007A   [0022] 
US20110159014A   [0022] 
US20040106161A   [0022] 
US20110117096A   [0022] 
US20040258685A   [0022] 
US20090148402A   [0022] 
US20090099344A   [0022] 
US20060034840A   [0022] 
US20110064737A   [0022] 
US20050276812A   [0022]  [0058]  [0059] 
US20080171040A   [0022] 
US20090202536A   [0022] 
US20060013819A   [0022] 
US20120107391A   [0022] 
US20060018899A   [0022] 
US20090285837A   [0022] 
US20110117097A   [0022] 
US20060088523A   [0022] 
US20100015157A   [0022] 
US20060121044A   [0022] 
US20080317753A   [0022] 
US20060165702A   [0022] 
US20090081223A   [0022] 
US20060188509A   [0022] 
US20090155259A   [0022] 
US20110165157A   [0022] 
US20060204505A   [0022] 
US20060212956A   [0022] 
US20060275305A   [0022]  [0033] 
US20120003217A   [0022] 
US20070009976A   [0022] 
US20070020261A   [0022] 
US20070037228A   [0022] 
US20100112603A   [0022] 
US20060067930A   [0022] 
US20070224203A   [0022] 
US20110064736A   [0022] 
US20080038271A   [0022] 
US20080050385A   [0022] 
US20100285010A   [0022] 
US20110223159A   [0022] 
US20100008975A   [0022] 
US20110245103A   [0022] 
US20110246399A   [0022] 
US20110027190A   [0022] 
US20100298156A   [0022] 
US20110151454A   [0022] 
US20110223619A   [0022] 
US20120107302A   [0022] 
US20090098135A   [0022] 
US20090148435A   [0022] 
US20090202546A   [0022] 
US20090226455A   [0022] 
US20090317387A   [0022] 
US20110044977A   [0022] 
US20120121586A   [0022] 
US20040014694A   [0033] 
US20050166993A   [0058]  [0059] 
WO2007044515A   [0058] 
US5208020A   [0059] 
US6441163B   [0059] 
US20110165155A   [0061] 
US20090202546A1   [0065] 

Global cancer statistics   [0005] 
Science   [0006] 
Cancer Res   [0006] 
CHEMICAL ABSTRACTS   [0007] 
Science   [0007] 
Science   [0007] 
New Engl. J. Med.   [0007] 
Mol Cell Biol   [0007] 
Cancer Immunol Immunother   [0007] 
Cancer Res.   [0007] 
Cancer Immunol Immunother   [0007] 
Proc. Annual Meeting Am Assoc Cancer Res   [0007] 
Proc Am Assoc Cancer Res   [0007] 
Seminars in Oncology   [0007] 
Nature Reviews: Molecular Cell Biology   [0007] 
J. Clin. Oncol.   [0008] 
N Engl J Med   [0008] 
J Clin Oncol   [0008] 
J Clin Oncol   [0008] 
T N Engl J Med   [0008] 
N Engl J Med   [0008] 
Breast Cancer Res Treat   [0008] 
Cancer Treat. Rev.   [0010] 
Cancer Treat Rep   [0010] 
Science   [0010] 
Chem Pharm Bull   [0010] 
Maytansine. Cancer Treat Rev   [0010] 
J. Clin. Oncol.   [0012] 
Cancer   [0012] 
Krop   [0013] 
New England Journal of Medicine   [0013] 
Oncogene   [0015] 
Nat Rev Mol Cell Biol   [0015] 
Nat Struct Biol   [0015] 
Nature   [0015] 
Pro Am Soc Cancer Res   [0015] 
Cancer Cell   [0016] 
Pro Am Soc Clin Oncol   [0017] 
Pro Am Soc Clin Oncol   [0017] 
J Clin Oncol, 2007 ASCO Annual Meeting Proceedings   [0018] 
J Clin Oncol, 2007 ASCO Annual Meeting Proceedings   [0018] 
J Clin Oncol 2007 ASCO Annual Meeting Proceedings   [0019] 
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine   [0023] 
Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome   [0023] 
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2 positive, node--negative tumors 1cm or smaller   [0023] 
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer   [0024] 
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer   [0025] 
Adjuvant Trastuzumab in HER2-positive breast cancer   [0026] 
Preoperative therapy with Trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study   [0027] 
Significantly higher pathologic complete remission rate after neoadjuvant therapy with Trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer   [0027] 
Neoadjuvant chemotherapy with Trastuzumab followed by adjuvant Trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort   [0027] 
Neoadjuvant treatment with Trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study   [0027] 
Pathologic complete response after neoadjuvant chemotherapy plus Trastuzumab predicts favorable survival in human epidermal growth factor receptor-2-overexpressing breast cancer : results from the TECHNO trial of the AGO and GBG study groups   [0027] 
HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials   [0027] 
Long-term follow-up of HER2-overexpressing Stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy   [0030] 
Efficacy of neoadjuvant therapy with Trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer   [0030] 
J. Natl. Cancer Inst.   [0032] 
J. Natl. Cancer Inst.   [0032] 
Successful quality assurance program for HER2 testing in the NSABP Trial for Herceptin   [0032] 
J. Natl. Cancer Inst.   [0032] 
Proceedings of the American Society of Clinical Oncology Thirty-Eighth Annual Meeting   [0032] 
Trialists' Group   [0032] 
26th Annual San Antonio Breast Cancer Symposium (SABCS)   [0032] 
Proc. ASCO   [0032] 
Antibodies, A Laboratory Manual   [0058]  [0058] 
Cancer Cell   [0058] 
CHEMICAL ABSTRACTS   [0058] 
CHEMICAL ABSTRACTS   [0058] 
CHEMICAL ABSTRACTS   [0058] 
CHEMICAL ABSTRACTS   [0058] 
CHEMICAL ABSTRACTS   [0058] 
Angew Chem. Intl. Ed. Engl.   [0058] 
CHEMICAL ABSTRACTS   [0059] 
Remington's Pharmaceutical Sciences   [0070]  [0074] 
Pharmaceutical Dosage Forms   [0074] 
Remington's Pharmaceutical Sciences   [0075] 
Interpreting the significance of changes in health-related quality-of-life scores   [0133]